|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found the frequency of GSTT1 null genotype of 19.2% in cases and 15.7% in controls, with an adjusted odds ratio (OR) of 1.4 (95% confidence interval (CI), 0.70-2.81), and a frequency of GSTM1 null genotype of 59% in cases with oxyphilic tumors and of 55.6% in controls (OR 1.24; 95% CI, 0.62-2.48), indicating that the GSTT1 and M1 null genotypes do not increase the risk of development of oxyphilic tumors.
|
16427734 |
2006 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Using in situ hybridization, we then demonstrated that GSTT1 transcripts are expressed in neoplastic cells of both tumour types.
|
16874663 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The contribution of cigarette smoking to sporadic colorectal cancer may differ according to molecular aspects of the tumor or according to glutathione S-transferase M1 (GSTM1) or glutathione S-transferase T1 (GSTT1) genotype.
|
15840612 |
2005 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
GSTT1 deletion was nearly significantly more common among glioblastoma cases with tumor p53 mutation than for those whose tumors did not have p53 mutation (OR 2.8; 95% CI 0.93-8.4; P = 0.07).
|
15006924 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The GSTM1 and GSTT1 genotypes did not show any correlation with the risk of the de novo diagnosed neoplasms.
|
15382272 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results obtained showed that the presence of three potentially risk alleles (GSTM1 null, GSTT1 null, and GSTP1 Ile/Ile) lead to a significant OR increase for all the cases, irrespective of the type of tumor (OR=2.91), for papillary (OR=3.64) but not for follicular tumors.
|
15120911 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that patients with carcinoma of the breast and inheritance of a combined gene deletion of GSTM1 and GSTT1 might bear an increased risk to develop a secondary therapy-induced hematologic neoplasia.
|
11792413 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In a multivariate analysis, the effects of GSTM1 null/GSTT1 null on survival were lost when residual disease and tumor grade were included.
|
11328408 |
2001 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.
|
11700265 |
2001 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, GSTP1val(105)/val(105) was protective against asthma symptoms and GSTT1 null was associated with a subgroup of basal cell carcinoma patients who develop large numbers of primary tumours in clusters.
|
11535245 |
2001 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Patients with colon tumours and who were homozygous GSTT1(*)2 genotype carriers were more likely than patients who expressed GSTT1 to have their DNA alkylated (83 versus 32%, P=0.03) and to have higher O(6)-MedG levels (0.178+/-0.374 versus 0.016+/-0.023 micromol O(6)-MedG/mol dG, P=0.04) in normal, but not tumour, DNA.
|
11448648 |
2001 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The combination of GSTT1 null/CCND1 GG was also associated with G3 tumors.
|
10498401 |
1999 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Similarly, no significant differences were obtained if GSTT1 and/or GSTM1 null genotypes were analyzed in subgroups of control subjects and ovarian cancer patients between the ages of 20-40, 41-70 and 71-90 years and in individuals with a positive family history of neoplastic disease.
|
9751255 |
1998 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
On the other hand, the combined null genotype of GSTM1 and GSTT1 was associated with proximal tumors.
|
9834266 |
1998 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
More than one tumour at first presentation (P <0.0001, hazard ratio 2.72) and GSTT1 null (P = 0.028, hazard ratio 1.74) were associated with decreased time to next primary tumour presentation.
|
9276622 |
1997 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The longitudinal study showed, after adjustment for age and tumour number at presentation, that GSTT1 null (P < 0.001, rate ratio 2.677) and CYP2D6 EM (P < 0.001, rate ratio 2.154) were significant determinants of accrual while CYP1A1 Ile/Ile was associated with slower accrual than the Ile/Val and Val/Val genotypes (P = 0.008, rate ratio 0.690).
|
8824510 |
1996 |